BrightGene Bio-Medical Technology Co Ltd
SSE:688166

Watchlist Manager
BrightGene Bio-Medical Technology Co Ltd Logo
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Watchlist
Price: 31.54 CNY 2.1% Market Closed
Market Cap: 13.3B CNY
Have any thoughts about
BrightGene Bio-Medical Technology Co Ltd?
Write Note

Operating Margin
BrightGene Bio-Medical Technology Co Ltd

16.6%
Current
22%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
16.6%
=
Operating Profit
206.2m
/
Revenue
1.2B

Operating Margin Across Competitors

Country CN
Market Cap 13.3B CNY
Operating Margin
17%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 749.7B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 3.3T DKK
Operating Margin
44%
Country US
Market Cap 372B USD
Operating Margin
28%
Country US
Market Cap 257.3B USD
Operating Margin
34%
Country CH
Market Cap 201.7B CHF
Operating Margin
32%
Country UK
Market Cap 163B GBP
Operating Margin
21%
Country CH
Market Cap 179.6B CHF
Operating Margin
31%
Country US
Market Cap 146B USD
Operating Margin
22%
No Stocks Found

BrightGene Bio-Medical Technology Co Ltd
Glance View

Market Cap
13.3B CNY
Industry
Pharmaceuticals

BrightGene Bio-Medical Technology Co., Ltd. engages in the research, development, and manufacturing of biopharmaceuticals, medicines as well as special generic active pharmaceutical ingredients and finished dosage forms. The company is headquartered in Suzhou, Jiangsu and currently employs 910 full-time employees. The company went IPO on 2019-11-08. The firm's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The firm's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The firm mainly conducts its businesses in domestic and overseas markets.

Intrinsic Value
22.57 CNY
Overvaluation 28%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
16.6%
=
Operating Profit
206.2m
/
Revenue
1.2B
What is the Operating Margin of BrightGene Bio-Medical Technology Co Ltd?

Based on BrightGene Bio-Medical Technology Co Ltd's most recent financial statements, the company has Operating Margin of 16.6%.